Cara Therapeutics Inc. (NASDAQ:CARA) saw a downside of -1.00% to close Friday at $2.98 after subtracting -$0.03 on the day. The 5-day average trading volume is 528,260 shares of the company’s common stock. It has gained $3.06 in the past week and touched a new high 2 times within the past 5 days. An average of 657,205 shares of the company has been traded in the last 20 days, and the 50-day average volume stands at 1,490,520.
CARA’s 1-month performance is 2.05% or -$0.08 on its low of $2.77 reached on 07/26/23. The company’s shares have touched a 52-week low of $2.57 and high of $12.81, with the stock’s rally to the 52-week high happening on 02/03/23. YTD, CARA has lost -72.25% or -$7.76 and has reached a new high 9 times. However, the current price is down -76.74% from the 52-week high price.
Top 5 AI Stocks to Buy for 2023
The artificial intelligence (AI) revolution is already here. And it's about to change everything we know about everything.
According to Grand View Research, the global AI boom could grow from about $137 billion in 2022 to more than $1.81 trillion by 2030. And investors like you always want to get in on the hottest stocks of tomorrow. Here are five of the best ways to profit from the AI boom.
Click Here to Download the FREE Report.
Sponsored
Insider Transactions
CARA stock investors last saw insider trading activity on Aug 03.Posner Christopher (President and CEO) most recently sold 4,307 shares at $3.07 per share on Aug 03. This transaction cost the insider $13,222. Chief Scientific Off,SVP-R&D, Menzaghi Frederique Ph.D., sold 2,993 shares at a price of $3.51 on Jun 23. Then, on Jun 23, Chief Medical Officer Goncalves Joana sold 2,723 shares at a price of $3.51 per share. This transaction amounted to $9,558.
Valuation Metrics
CARA stock has a beta of 0.85. Moving on to other valuation ratios, the trailing price-to-sales (P/S) ratio is 5.99 while the price-to-book (PB) in the most recent quarter is 1.48.
Cara Therapeutics Inc.’s quick ratio for the period ended June 29 was 4.80, with the current ratio over the same period at 4.90. In terms of profitability, the gross margin trailing 12 months is 66.20%. The trailing 12-month EBITDA margin is -205.09%. The firm’s gross profit as reported stood at $34.6 million against revenue of $41.87 million.
Earnings Surprise
For the quarterly period ending June 29 this year, Net income and sales went up compared to those figures reported in the previous quarter. Net income grew 86.63% to -$31.48 million, while revenue of -$26.67 million was 15.28% off the previous quarter. Analysts expected CARA to announce -$0.54 per share in earnings in its latest quarter, but it posted -$0.58, representing a -7.40% surprise. EBITDA for the quarter stood at more than -$31.86 million. CARA stock balance sheet for the quarter ending June 29 shows that total liabilities totaled 25.46 million, with total debt at $0.98 million. Shareholders hold equity totaling $54.08 million.
Let’s look briefly at Cara Therapeutics Inc. (CARA) price momentum from a technical analysis perspective. The 9-day relative strength index as at close on 18 August was 46.55% to suggest the stock is trending Neutral, with historical volatility in this time period at 70.71%.
The stock’s 5-day moving average is $2.98, reflecting a -2.93% or -$0.09 change from its current price. CARA is currently trading +1.02% above its 20-day SMA, -40.93% above its 100-day SMA. However, the stock’s current price level is away from the SMA50 by -12.09% and SMA200 by-68.30%.
Stochastic %K and %D was 23.54% and 23.81% and the average true range (ATR) pointed at 0.16. The RSI (14) points at 47.26%, while the 14-day stochastic is at 28.00% with the period’s ATR at 0.18. The stock’s 9-day MACD Oscillator is pointing at -0.03 and -0.07 on the 14-day charts.
Analyst Ratings
In the most recent analyst report for Cara Therapeutics Inc. (NASDAQ: CARA), BofA Securities downgraded it to an Underperform rating. They previously had a Neutral rating on the stock. Analysts offering their rating for CARA stock have a consensus rating for the stock as Buy. Currently, 0 brokerage advisors rate CARA as a “sell,”, while 0 advise that investors “Hold.” 1 analysts have rated the stock as underweight. 0 rates the stock as overweight while 6 have offered a “buy” rating.
What is CARA’s price target for the next 12 months?
Analysts have a consensus price target ranging from a low of $3.50 and a high of $25.00, with their median price target at $18.00. Looking at these predictions, the average price target given by analysts is for Cara Therapeutics Inc. (CARA) stock is $16.93.
